Abstract
Interventional cardiology has witnessed several revolutionary developments over the last two decades leading to progressive changes in daily practice. The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES). Drug-eluting stents made a revolution in interventional cardiology, not only by improving the mechanical limitations of balloon angioplasty but also by radically decreasing restenosis rates [1, 2]. Last-generation DESs have shown to decrease 12-month restenosis rates to single digits; however, concerns still exist regarding the rare but unpredictable occurrence of late or very late stent thrombosis, a catastrophic event resulting from delayed vessel healing [3, 4]. Current guidelines recommend the use of prolonged double antiplatelet therapy (DAPT) following DES implantation which may become problematic in specific clinical settings where a shorter DAPT period is desired (i.e., high-bleeding-risk patients) [5].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fischman DL, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent restenosis study investigators. N Engl J Med. 1994;331(8):496–501.
Holmes DR Jr, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53(12):77c–81c.
Nakazawa G, et al. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging. 2009;2(5):625–8.
Finn AV, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27(7):1500–10.
Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213–60.
Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horseradish peroxidase. A new catheter approach. Atherosclerosis. 1987;65(3):215–25.
Cremers B, et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost. 2009;101(1):201–6.
Wessely R, et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery. Thromb Haemost. 2007;97(6):1003–12.
Dangas GD, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013;6(9):914–22.
Edelman ER, Adams DH, Karnovsky MJ. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci U S A. 1990;87(10):3773–7.
Muller DW, et al. Intramural methotrexate therapy for the prevention of neointimal thickening after balloon angioplasty. J Am Coll Cardiol. 1992;20(2):460–6.
Gradus-Pizlo I, et al. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery. J Am Coll Cardiol. 1995;26(6):1549–57.
Scheller B, et al. Acute cardiac tolerance of current contrast media and the new taxane protaxel using iopromide as carrier during porcine coronary angiography and stenting. Investig Radiol. 2002;37(1):29–34.
Scheller B, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110(7):810–4.
Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004–14.
Granada JF, et al. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1(1):e000117.
Kelsch B, et al. Dose response to Paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model. Investig Radiol. 2011;46(4):255–63.
Berg MC, et al. Drug-coated angioplasty balloon catheters: coating compositions and methods. Adv Eng Mater. 2012;14:B45–50.
Cremers B, et al. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009;98(5):325–30.
Yeh TK, et al. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res. 2005;22(6):867–74.
Radke PW, et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention. 2011;7(6):730–7.
Kempin W, et al. In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. Eur J Pharm Biopharm. 2015;96:322–8.
Axel DI, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96(2):636–45.
Katsanos K, et al. Systematic review and meta-analysis of randomized controlled trials of paclitaxel-coated balloon angioplasty in the femoropopliteal arteries: role of paclitaxel dose and bioavailability. J Endovasc Ther. 2016;23(2):356–70.
Kolodgie FD, et al. Comparison of particulate embolization after femoral artery treatment with IN.PACT Admiral versus Lutonix 035 paclitaxel-coated balloons in healthy swine. J Vasc Interv Radiol. 2016;27(11):1676–1685.e2.
Gongora CA, et al. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015;8(8):1115–23.
Milewski K, et al. Evaluation of efficacy and dose response of different paclitaxel-coated balloon formulations in a novel swine model of iliofemoral in-stent restenosis. JACC Cardiovasc Interv. 2012;5(10):1081–8.
Yazdani SK, et al. Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model. Catheter Cardiovasc Interv. 2014;83(1):132–40.
Rosenfield K, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–53.
Schneider PA, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11(1):e005891.
Kedhi E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet. 2010;375(9710):201–9.
Stone GW, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362(18):1663–74.
Buszman PP, et al. Stent healing response following delivery of paclitaxel via durable polymeric matrix versus iopromide-based balloon coating in the familial hypercholesterolaemic swine model of coronary injury. EuroIntervention. 2013;9(4):510–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Ferrone, M., Granada, J.F. (2019). Technical Insights on Drug-Coated Balloons. In: Cortese, B. (eds) Drug-Coated Balloons . Springer, Cham. https://doi.org/10.1007/978-3-319-92600-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-92600-1_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92599-8
Online ISBN: 978-3-319-92600-1
eBook Packages: MedicineMedicine (R0)